Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia

Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724 · see citing works

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works

Dopamine in schizophrenia: a review and reconceptualization

Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,021 · see citing works

Consensus Nomenclature for <i>in vivo</i> Imaging of Reversibly Binding Radioligands

Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow &amp; Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955 · see citing works

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · see citing works

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method

Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · see citing works

Relationship Between Dopamine D ₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works

Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins

Tu, J. C., Xiao, B., Naisbitt, S. R., Yuan, J. P., Petralia, R. S., Brakeman, P., Doan, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80810-7 · Cited by 1,047 · see citing works

Increased baseline occupancy of D ₂ receptors by dopamine in schizophrenia

Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · see citing works

Shank, a Novel Family of Postsynaptic Density Proteins that Binds to the NMDA Receptor/PSD-95/GKAP Complex and Cortactin

Naisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, C., Valtschanoff, J., Weinberg, R. J., Worley, P. F., & Sheng, M. (1999) · Neuron · doi:10.1016/s0896-6273(00)80809-0 · Cited by 1,009 · see citing works

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Abi-Dargham, A., Gil, R. B., Krystal, J., Baldwin, R., Seibyl, J., Bowers, M., van Dyck, C., Charney, D., Innis, R., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 860 · see citing works

Prefrontal Dopamine D₁Receptors and Working Memory in Schizophrenia

Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · see citing works

N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency

Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721 · see citing works

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710 · see citing works

Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics

Malhotra, A. K. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 681 · see citing works

Effects of Ketamine in Normal and Schizophrenic Volunteers

Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · see citing works

Metabotropic glutamate receptors

Ferraguti, F., & Shigemoto, R. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0266-5 · Cited by 647 · see citing works

Mice Lacking Metabotropic Glutamate Receptor 5 Show Impaired Learning and Reduced CA1 Long-Term Potentiation (LTP) But Normal CA3 LTP

Lu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634 · see citing works

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 576 · see citing works

N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial

Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552 · see citing works

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540 · see citing works

Provocative tests with psychostimulant drugs in schizophrenia

Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 535 · see citing works

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527 · see citing works

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524 · see citing works

<i>N</i>-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494 · see citing works

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

Kegeles, L., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J., Heertum, R. V. V., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 425 · see citing works

Alterations of Benzodiazepine Receptors in Type II Alcoholic Subjects Measured With SPECT and [123I]Iomazenil

Abi‐Dargham, A., Krystal, J. H., Anjilvel, S., Scanley, B. E., Zoghbi, S. S., Baldwin, R. M., Rajeevan, N., Ellis, S. P., Petrakis, I. L., Seibyl, J. P., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1550 · Cited by 405 · see citing works

Glutamate and Glutamine Measured With 4.0 T Proton MRS in Never-Treated Patients With Schizophrenia and Healthy Volunteers

Théberge, J., Bartha, R., Drost, D. J., Menon, R. S., MALLA, A. K., Takhar, J., Neufeld, R. W. J., Rogers, J. S., Pavlosky, W. F., Schaefer, B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1944 · Cited by 398 · see citing works

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?

Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 397 · see citing works

Elevated dopa decarboxylase activity in living brain of patients with psychosis

Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342 · see citing works

Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia

Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T. E., Egan, M. F., Pickar, D., & Breier, A. F. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337 · see citing works

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients

Hietala, J. A., Syvälahti, E. K. G., Kuoppamäki, M., Hietala, J., Syvälahti, E. K. G., Haaparanta‐Solin, M., Kuoppamäki, M., Ruotsalainen, U., Vuorio, K. A., Räkköläinen, V., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91801-9 · Cited by 321 · see citing works

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons

Pisani, A., Gubellini, P., Bonsi, P., Conquet, F., Picconi, B., Centonze, D., Bernardi, G., & Calabresi, P. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00297-4 · Cited by 311 · see citing works

Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study

Rowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., Barrow, R., Yeo, R., Lauriello, J., & Brooks, W. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.394 · Cited by 304 · see citing works

Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy

Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296 · see citing works

Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology

Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295 · see citing works

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001751 · Cited by 278 · see citing works

Reduced Metabotropic Glutamate Receptor 5 Density in Major Depression Determined by [¹¹C]ABP688 PET and Postmortem Study

Deschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278 · see citing works

Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania

Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M. Y., Cohen, B. M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.014 · Cited by 272 · see citing works

MODEL PSYCHOSES AND SCHIZOPHRENIA

Luby, E. D., Gottlieb, J. S., Cohen, B. D., Rosenbaum, G., & Domino, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268 · see citing works

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256 · see citing works

NMDA receptor channels: Subunit-specific potentiation by reducing agents

Köhr, G., Eckardt, S., Lüddens, H., Monyer, H., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90311-5 · Cited by 255 · see citing works

Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

McGowan, S., Lawrence, A., Sales, T., Quested, D., & Grasby, P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.134 · Cited by 251 · see citing works

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

de la Fuente-Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D., Ramírez-Bermúdez, J., & Graff-Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 248 · see citing works

Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume

Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231 · see citing works

Measurement of Glutamate and Glutamine in the Medial Prefrontal Cortex of Never-Treated Schizophrenic Patients and Healthy Controls by Proton Magnetic Resonance Spectroscopy

Bartha, R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220085012 · Cited by 230 · see citing works

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach

Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2 · Cited by 226 · see citing works

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans

Vollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223 · see citing works

Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents

Kinney, G. G., Burno, M., Campbell, U. C., Hernández, L. M., Rodriguez, D. E., Bristow, L. J., & Conn, P. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219 · see citing works

mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning

Ayala, J. E., Chen, Y., Banko, J. L., Sheffler, D. J., Williams, R. D., Telk, A. N., Watson, N. L., Xiang, Z., Zhang, Y., Jones, P. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.30 · Cited by 206 · see citing works

Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study

Matsuzawa, D., Obata, T., Shirayama, Y., Nonaka, H., Kanazawa, Y., Yoshitome, E., Takanashi, J., Matsuda, T., Shimizu, E., Ikehira, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001944 · Cited by 201 · see citing works

Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects

G Smith, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00092-4 · Cited by 201 · see citing works

Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194 · see citing works

Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus

Uslaner, J. M., Parmentier‐Batteur, S., Flick, R. B., Surles, N. O., Lam, J. S. H., McNaughton, C. H., Jacobson, M. A., & Hutson, P. H. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.022 · Cited by 193 · see citing works

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

Théberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.033670 · Cited by 185 · see citing works

Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.

Ametamey, S. M., Kessler, L. J., Honer, M., Wyss, M. T., Buck, A., Hintermann, S., Auberson, Y. P., Gasparini, F., & Schubiger, P. A. (2006) · PubMed · Cited by 183 · see citing works

ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities

Liu, F., Grauer, S. M., Kelley, C., Navarra, R. L., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X. Z., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136580 · Cited by 183 · see citing works

Glutamate Levels in the Associative Striatum Before and After 4 Weeks of Antipsychotic Treatment in First-Episode Psychosis

de la Fuente‐Sandoval, C., León-Ortíz, P., Azcárraga, M., Stephano, S., Favila, R., Díaz-Galvis, L., Alvarado-Alanis, P., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.289 · Cited by 181 · see citing works

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180 · see citing works

Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia

Steullet, P., Neijt, H. C., Cuénod, M., & Do, K. Q. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.014 · Cited by 173 · see citing works

PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia

Karlsson, P., Farde, L., Halldin, C., & Sedvall, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.761 · Cited by 172 · see citing works

Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users

Narendran, R., Frankle, W. G., Keefe, R. S. E., Gil, R. B., Martínez, D., Slifstein, M., Kegeles, L. S., Talbot, P. S., Huang, Y. H., Hwang, D., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2352 · Cited by 170 · see citing works

Translating Glutamate: From Pathophysiology to Treatment

Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168 · see citing works

Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia

Egerton, A., Brugger, S. P., Raffin, M., Barker, G. J., Lythgoe, D. J., McGuire, P. K., & Stone, J. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.113 · Cited by 168 · see citing works

Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy Study

van Elst, L. T., Valerius, G., Büchert, M., Thiel, T., Rüsch, N., Bubl, E., Hennig, J., Ebert, D., & Olbrich, H. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.041 · Cited by 164 · see citing works

1H-MRS at 4 Tesla in minimally treated early schizophrenia

Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153 · see citing works

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

Miller, D. W., & Abercrombie, E. D. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02144-2 · Cited by 146 · see citing works

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

Henry, S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00332-5 · Cited by 145 · see citing works

White Matter Alterations in Deficit Schizophrenia

Rowland, L. M., Spieker, E. A., Francis, A., Barker, P. B., Carpenter, W. T., & Buchanan, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.207 · Cited by 144 · see citing works

Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-(( S )-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia

Pinard, E., Alanine, A. I., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., Brom, V., Burner, S., Fischer, H., Hainzl, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100210p · Cited by 135 · see citing works

N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development

das Neves Duarte, J. M., Kulak, A., Gholam-Razaee, M. M., Cuenod, M., Gruetter, R., & Do, K. Q. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.035 · Cited by 124 · see citing works

Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia

Reid, M. A., Stoeckel, L. E., White, D. M., Avsar, K. B., Bolding, M., Akella, N. S., Knowlton, R. C., den Hollander, J. A., & Lahti, A. C. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.013 · Cited by 122 · see citing works

Increased prefrontal cortical D 1 receptors in drug naïve patients with schizophrenia: a PET study with [ 11 C]NNC112

Abi‐Dargham, A., Xu, X., Thompson, J. L., Gil, R. B., Kegeles, L. S., Urban, N., Narendran, R., Hwang, D., Laruelle, M. A., & Slifstein, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111409265 · Cited by 120 · see citing works

Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis

Fusar‐Poli, P. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.46 · Cited by 117 · see citing works

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study

Ohrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heindel, W., & Pfleiderer, B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.002 · Cited by 116 · see citing works

Contribution of Cystine–Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine

Baker, D. L., Madayag, A., Kristiansen, L. V., Meador‐Woodruff, J. H., Haroutunian, V. H., & Raju, I. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301532 · Cited by 112 · see citing works

Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS)

Tayoshi, S., Sumitani, S., Taniguchi, K., Shibuya‐Tayoshi, S., Numata, S., Iga, J., Nakataki, M., Ueno, S., Harada, M., & Ohmori, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.014 · Cited by 111 · see citing works

NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans

Kegeles, L., Martinez, D., Kochan, L., Hwang, D., Huang, Y., Mawlawi, O., Suckow, R., Heertum, R. V. V., & Laruelle, M. (2002) · Synapse · doi:10.1002/syn.10010 · Cited by 106 · see citing works

Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation

Wood, S. J., Berger, G. E., Wellard, R. M., Proffitt, T., McConchie, M., Berk, M., McGorry, P. D., & Pantelis, C. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.018 · Cited by 105 · see citing works

Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

Aoyama, N., Théberge, J., Drost, D. J., Manchanda, R., Northcott, S., Neufeld, R. W. J., Menon, R. S., Rajakumar, N., Pavlosky, W. F., Densmore, M., et al. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.079608 · Cited by 105 · see citing works

18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry

Wong, D. F., Waterhouse, R. N., Kuwabara, H., Kim, J., Brašić, J. R., Chamroonrat, W., Stabins, M., Holt, D. P., Dannals, R. F., Hamill, T. G., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107995 · Cited by 105 · see citing works

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study

Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103 · see citing works

Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction

Chang, L., Friedman, J. I., Ernst, T., Zhong, K., Tsopelas, N. D., & Davis, K. L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.025 · Cited by 101 · see citing works

Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study

Ohrmann, P., Siegmund, A., Suslow, T., Spitzberg, K., Kersting, A., Arolt, V., Heindel, W. L., & Pfleiderer, B. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.08.021 · Cited by 100 · see citing works

An In Vivo Proton Magnetic Resonance Spectroscopy Study of Schizophrenia Patients

Stanley, J. A., Williamson, P., Drost, D. J., Rylett, R. J., Carr, T. J., MALLA, A. K., & Thompson, R. T. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.597 · Cited by 98 · see citing works

Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study

Olbrich, H. M., Valerius, G., Rüsch, N., Büchert, M., Thiel, T., Hennig, J., Ebert, D., & van Elst, L. T. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227811 · Cited by 96 · see citing works

Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man

Aalto, S., Ihalainen, J. A., Hirvonen, J., Kajander, J., Scheinin, H., Tanila, H., Någren, K., Vilkman, H., Gustafsson, L. L., Syvälahti, E. K. G., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0092-6 · Cited by 95 · see citing works

Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia

Terpstra, M., Vaughan, T. J., Uǧurbil, K., Lim, K. O., Schulz, S. C., & Rolf Gruetter, A. (2005) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-005-0012-0 · Cited by 95 · see citing works

Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla

Bustillo, J., Chen, H., Gasparovic, C., Mullins, P. G., Caprihan, A., Qualls, C., Apfeldorf, W. J., Lauriello, J., & Posse, S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.024 · Cited by 94 · see citing works

Synapse structure: glutamate receptors connected by the shanks

Ehlers, M. D. (1999) · Current Biology · doi:10.1016/s0960-9822(00)80043-3 · Cited by 93 · see citing works

Increased Metabotropic Glutamate Receptor Subtype 5 Availability in Human Brain After One Night Without Sleep

Hefti, K., Holst, S. C., Sóvágó, J., Bachmann, V., Buck, A., Ametamey, S. M., Scheidegger, M., Berthold, T., Gomez‐Mancilla, B., Seifritz, E., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.030 · Cited by 93 · see citing works

Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study

de la Fuente‐Sandoval, C., León-Ortíz, P., Azcárraga, M., Favila, R., Stephano, S., & Graff‐Guerrero, A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000314 · Cited by 88 · see citing works

First-Episode Schizophrenia

Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 87 · see citing works

Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia

Chavez-Noriega, L. E., Schaffhauser, H., & Campbell, U. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339337 · Cited by 85 · see citing works

Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia

Kraguljac, N. V., Reid, M. A., White, D. M., den Hollander, J., & Lahti, A. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.126 · Cited by 84 · see citing works

The Selective mGlu5 Receptor Antagonist MTEP, Similar to NMDA Receptor Antagonists, Induces Social Isolation in Rats

Koroś, E., Rosenbrock, H., Birk, G., Weiss, C., & Sams‐Dodd, F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301133 · Cited by 82 · see citing works

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

Dean, O. M., Bush, A. I., Berk, M., Copolov, D., & van den Buuse, M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.017 · Cited by 81 · see citing works

Observation of Metabolic Changes in Chronic Schizophrenia After Neuroleptic Treatment by In Vivo Hydrogen Magnetic Resonance Spectroscopy

Choe, B., Suh, T. S., Shinn, K.-S., Lee, C., Lee, C., & Paik, I. (1996) · Investigative Radiology · doi:10.1097/00004424-199606000-00006 · Cited by 79 · see citing works

A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients

Bartha, R., Al-Semaan, Y. M., Williamson, P., Drost, D. J., MALLA, A. K., Carr, T. J., Densmore, M., Canaran, G., & Neufeld, R. W. J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00007-4 · Cited by 77 · see citing works

Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus

Yoo, S. Y., Yeon, S., Choi, C., Kang, D.-H., Lee, J., Shin, N. Y., Jung, W. H., Choi, J., Jang, D., & Kwon, J. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.036 · Cited by 76 · see citing works

The Effect of Risperidone on Metabolite Measures in the Frontal Lobe, Temporal Lobe, and Thalamus in Schizophrenic Patients. A Proton Magnetic Resonance Spectroscopy (1H MRS) Study

Szulc, A., Galińska-Skok, B., Tarasów, E., Dzienis, W., Kubas, B., Konarzewska, B., Walecki, J. M., Alathiaki, A. S., & Czernikiewicz, A. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-873156 · Cited by 72 · see citing works

Neurochemical and structural correlates of executive dysfunction in schizophrenia

Rüsch, N., van Elst, L. T., Valerius, G., Büchert, M., Thiel, T., Ebert, D., Hennig, J., & Olbrich, H. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.024 · Cited by 72 · see citing works

in vivo Variation in Metabotropic Glutamate Receptor Subtype 5 Binding Using Positron Emission Tomography and [ 11 C]ABP688

DeLorenzo, C., Kumar, J. S. D., Mann, J. J., & Parsey, R. V. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.105 · Cited by 72 · see citing works

Kinetic Analysis of the Metabotropic Glutamate Subtype 5 Tracer [ 18 F]FPEB in Bolus and Bolus-Plus-Constant-Infusion Studies in Humans

Sullivan, J. M., Lim, K., Labaree, D. C., Lin, S.-F., McCarthy, T. J., Seibyl, J. P., Tamagnan, G. D., Huang, Y. H., Carson, R. E., Ding, Y., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.195 · Cited by 72 · see citing works

Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study

Block, W., Bayer, T. A., Tepest, R., Träber, F., Rietschel, M., Müller, D. J., Schulze, T. G., Honer, W. G., Maier, W., Schild, H. H., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01264-7 · Cited by 71 · see citing works

Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy

Ohrmann, P., Kugel, H., Bauer, J., Siegmund, A., Kölkebeck, K., Suslow, T., Wiedl, K. H., Rothermundt, M., Arolt, V., & Pedersen, A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.005 · Cited by 70 · see citing works

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

Brody, S. A., Conquet, F., & Geyer, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1635-3 · Cited by 69 · see citing works

Ketamine does not decrease striatal dopamine D 2 receptor binding in man

Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Någren, K., Vilkman, H., Gustafsson, L. L., Syvälahti, E. K. G., & Hietala, J. A. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1236-6 · Cited by 69 · see citing works

Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge

Miyake, N., Skinbjerg, M., Easwaramoorthy, B., Kumar, D. J. S., Girgis, R. R., Xu, X., Slifstein, M., & Abi‐Dargham, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.023 · Cited by 67 · see citing works

Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study

Taylor, M. J., Tiangga, E. R., Mhuircheartaigh, R. N., & Cowen, P. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405359 · Cited by 66 · see citing works

Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging

Hutcheson, N. L., Reid, M. A., White, D. M., Kraguljac, N. V., Avsar, K. B., Bolding, M., Knowlton, R. C., den Hollander, J. A., & Lahti, A. C. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.039 · Cited by 65 · see citing works

Preliminary study of frontal lobe 1H MR spectroscopy in childhood‐onset schizophrenia

Thomas, M. A., Ke, Y., Levitt, J. G., Caplan, R., Curran, J. G., Asarnow, R. F., & McCracken, J. T. (1998) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880080413 · Cited by 61 · see citing works

Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: A proton magnetic resonance spectroscopy study at 3 T

Wood, S. J., Yücel, M., Wellard, R. M., Harrison, B. J., Clarke, K., Fornito, A., Velakoulis, D., & Pantelis, C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.008 · Cited by 60 · see citing works

In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons

DeLorenzo, C., Milak, M. S., Brennan, K. G., Kumar, J. S. D., Mann, J. J., & Parsey, R. V. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1723-7 · Cited by 60 · see citing works

Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A 1H spectroscopy study

Keshavan, M. S., Dick, R. M., Diwadkar, V. A., Montrose, D. M., Prasad, K. M. R., & Stanley, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.012 · Cited by 59 · see citing works

Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis

Valli, I., Stone, J. M., Mechelli, A., Bhattacharyya, S., Raffin, M., Allen, P., Fusar‐Poli, P., Lythgoe, D. J., Tuura, R., Seal, M. L., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.033 · Cited by 59 · see citing works

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia

Yoshimura, R., Gotō, N., Kakeda, S., Nishimura, J., Moriya, J., Hayashi, K., Hori, H., Ikenouchi, A., Umen-Nakano, W., Katsuki, A., et al. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s25582 · Cited by 58 · see citing works

Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo

Bressan, R. A., Erlandsson, K., Stone, J. M., Mulligan, R. S., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.016 · Cited by 57 · see citing works

Behavioral and biochemical effects of glutathione depletion in the rat brain

Cruz-Aguado, R., Almaguer‐Melian, W., Díaz, C. M., et al. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00484-1 · Cited by 53 · see citing works

Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome

Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 51 · see citing works

Proton Magnetic Resonance Spectroscopy Study of Brain Metabolite Changes after Antipsychotic Treatment

Szulc, A., Galińska-Skok, B., Tarasów, E., Waszkiewicz, N., Konarzewska, B., Popławska, R., Bibulowicz, D., Simonienko, K., & Walecki, J. M. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1279739 · Cited by 51 · see citing works

Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1

Gunn, R. N., Murthy, V., Catafau, A. M., et al. (2011) · Synapse · doi:10.1002/syn.20966 · Cited by 50 · see citing works

Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia.

Galińska-Skok, B., Szulc, A., Tarasów, E., Kubas, B., Dzienis, W., Czernikiewicz, A., & Walecki, J. M. (2009) · PubMed · Cited by 50 · see citing works

Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors

Javitt, D., Hashim, A., & Sershen, H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300589 · Cited by 48 · see citing works

Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers

Martin‐Facklam, M., Pizzagalli, F., Zhou, Y., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.212 · Cited by 48 · see citing works

Improved selectivity of double quantum coherence filtering for the detection of glutathione in the human brain in vivo

Trabesinger, A. H., & Boesiger, P. (2001) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1094 · Cited by 42 · see citing works

Test‐retest stability of cerebral mGluR 5 quantification using [ 11 C]ABP688 and positron emission tomography in rats

Elmenhorst, D., Aliaga, A., Bauer, A., & Rosa‐Neto, P. (2012) · Synapse · doi:10.1002/syn.21542 · Cited by 35 · see citing works

The synthesis and preclinical evaluation in rhesus monkey of [18F]MK‐6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers

Hamill, T. G., Eng, W., Jennings, A. S. R., Lewis, R. T., Thomas, S., Wood, S., Street, L. J., Wisnoski, D. D., Wolkenberg, S. E., Lindsley, C. W., et al. (2010) · Synapse · doi:10.1002/syn.20842 · Cited by 34 · see citing works

Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia

Seese, R. R., O’Neill, J., Hudkins, M. R., Siddarth, P., Levitt, J. G., Tseng, B., Wu, K. N., & Caplan, R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.011 · Cited by 30 · see citing works

Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation

Ota, M., Ishikawa, M., Sato, N., Hori, H., Sasayama, D., Hattori, K., Teraishi, T., Nakata, Y., & Kunugi, H. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01853.x · Cited by 29 · see citing works

New double quantum coherence filter for localized detection of glutathione in vivo

Zhao, T., Heberlein, K., Jonas, C. R., et al. (2006) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20788 · Cited by 29 · see citing works

Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans

Wong, D. F., Ostrowitzki, S., Zhou, Y., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.052 · Cited by 26 · see citing works

Cell-type specificity of mGluR activation in striatal neuronal subtypes

Pisani, A., Bernardi, G., Bonsi, P., et al. (2000) · Amino Acids · doi:10.1007/s007260070040 · Cited by 25 · see citing works

Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla

Théberge, J., Al-Semaan, Y. M., Jensen, J. E., et al. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.08.001 · Cited by 22 · see citing works

Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET

Bressan, R. A., Erlandsson, K., Mulligan, R. S., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.027 · Cited by 16 · see citing works

Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET

Bullich, S., Slifstein, M., Passchier, J., et al. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0398-6 · Cited by 16 · see citing works

Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: A potential PET tracer for studying glutathione transferase

Huang, H.-L., Yeh, C., Chang, K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.091 · Cited by 10 · see citing works

Detection of head and neck cancer with 99Tcm glutathione: a correlative study with tissue glutathione and glutathione

Çağlar, M., I, I. I., AL, H., et al. (2001) · Nuclear Medicine Communications · doi:10.1097/00006231-200101000-00005 · Cited by 5 · see citing works

Comparative study of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK6577 in baboons

Zheng, M., Holden, D., Hamill, T. G., et al. (2013) · Journal of Nuclear Medicine · Cited by 4 · see citing works

Double Quantum Coherence

Munowitz, M. G. (2007) · Encyclopedia of Magnetic Resonance · doi:10.1002/9780470034590.emrstm0131 · Cited by 2 · see citing works

An integrative perspective on the role of dopamine in schizophrenia

Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293 · see citing works

Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?

Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262 · see citing works

Altered Cortical Ensembles in Mouse Models of Schizophrenia

Hamm, J. P., Peterka, D. S., Gogos, J. A., & Yuste, R. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.019 · Cited by 175 · see citing works

Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain?

Jardri, R., Hugdahl, K., Hughes, M., Brunelin, J., Waters, F., Alderson-Day, B., Smailes, D., Sterzer, P., Corlett, P. R., Leptourgos, P., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw075 · Cited by 157 · see citing works

Development of targeted alpha particle therapy for solid tumors.

Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157 · see citing works

Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders

Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132 · see citing works

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100 · see citing works

Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study

Hugdahl, K., Craven, A. R., Nygård, M., Løberg, E.-M., Berle, J. Ø., Johnsen, E., Kroken, R., Specht, K., Andreassen, O. A., & Ersland, L. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.015 · Cited by 64 · see citing works

Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders

Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39 · see citing works

Acute Ketamine Infusion in Rat Does Not Affect In Vivo [ ¹¹ C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5

Kosten, L., Verhaeghe, J., wyffels, L., Stroobants, S., & Staelens, S. (2018) · Molecular Imaging · doi:10.1177/1536012118788636 · Cited by 17 · see citing works

Neurochemical dysfunction in motor cortex and hippocampus impairs the behavioral performance of rats chronically exposed to inorganic mercury

Teixeira, F. B., Leão, L. K. R., Bittencourt, L. O., et al. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.12.008 · Cited by 27 · see citing works

Glutamatergic neurotransmission in aging: a critical perspective

Segovia, G., Porras, A., Arco, A. D., & Mora, F. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00225-6 · Cited by 375 · see citing works

Age-related effects of NMDA-stimulated concomitant release of nitric oxide and glutamate in cortical slices prepared from DBA/2 mice

Rowley, H. L., Ellis, Y., & Davies, J. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)90452-s · Cited by 14 · see citing works

Repeated Restraint Stress Alters Hippocampal Glutamate Uptake and Release in the Rat

Fontella, F. U., Vendite, D., Tabajara, Â. S., Porciúncula, L. O., Torres, I. L. D. S., Jardim, F. M. A., Martini, L., Souza, D. O., Netto, C. A., & Dalmaz, C. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000035805.46592.6c · Cited by 74 · see citing works

Anatomy of Putative Glutamatergic Neurons

Storm‐Mathisen, J., & Ottersen, O. P. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0925-3_4 · Cited by 59 · see citing works